Radiopharm Theranostics Limited income statement RDPTF

Annual Quarterly

In fiscal 2025, which ended Jun 30, 2025, Radiopharm Theranostics Limited reported revenue of $3.6 million. It recorded a net loss of $38.3 million. The operating loss came to $38.2 million, an operating margin of -1050.6%. Diluted earnings per share were -$1.76.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Jun 30, 2025
Revenue
4
Cost of revenue
4
Gross profit
0
Research and development
28
Selling, general and administrative
15
Operating income
-38
Finance costs
0
Pretax income
-38
Income tax
0
Net income
-38
Basic EPS
-1.76
Diluted EPS
-1.76
Weighted average shares, basic
2,081
Weighted average shares, diluted
2,081
Other measures
Interest coverage
-584.59x
Margins
Gross margin
1.08%
Operating margin
-1,050.63%
Pretax margin
-1,052.43%
Profit margin
-1,055.27%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RADX (Nasdaq), RDPTF (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Carlton Vic
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1949257

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.